A nationwide recall has been issued for 12 packages of levothyroxine sodium tablets, a common thyroid medication, by Major Rugby. The recall, announced in a letter to retailers, states that these tablets are 'subpotent,' delivering less medication than intended but are 'not likely to cause adverse health effects.' Consumers are advised to return the tablets and consult their doctor if they possess any recalled product. The affected packages include various dosages (25 mcg to 150 mcg) and specific lot numbers with expiration dates ranging from July 2026 to January 2027. Levothyroxine sodium is used to treat hypothyroidism and related conditions.

Product Recalls

Add Topic

Nationwide recall issued for this thyroid medication. See products

Drew Pittock

USA TODAY

Updated July 27, 2026, 8:34 p.m. ET

Hear this story

Share to Facebook Share to Twitter Share by email

Major Rugby, a pharmaceutical manufacturer that produces levothyroxine sodium tablets, issued a nationwide recall for the common thyroid medication, according to a letter it sent to retailers earlier this month.

While consumers are being urged to return their medicine to the point of purchase, Major Rugby said in its letter that taking them "is not likely to cause adverse health effects."

Here’s what you should know about the recalled products and how to identify them.

Major Rugby, a pharmaceutical manufacturer that produces levothyroxine sodium tablets, issued a nationwide recall for the common thyroid medication.

12 levothyroxine sodium tablet packages recalled

Major Rugby issued a recall for 12 of its levothyroxine sodium tablet packages, including individual packs of 10 and boxes containing 10 blister packs.

The Mayo Clinic notes that levothyroxine sodium tablets are used to treat hypothyroidism, enlarged thyroid glands and a type of thyroid cancer.

The tablets, sold under the Major and Cardinal brand names, were distributed nationwide beginning in January 2025, according to Major Rugby’s recall letter sent to retailers.

Supplier: Recalled medication 'not likely to cause adverse health effects'

Major Rugby said in its letter that taking the recalled medication "is not likely to cause adverse health effects," though it suggests returning the tablets to the place of purchase.

According to the letter and a report from the Food and Drug Administration, the recalled pills are "subpotent," meaning they deliver less medication than they’re supposed to.

Customers should also consult their doctor or physician if they find the recalled product in their medicine cabinet.

Full list of recalled packages

Below are the affected packages, all of which require a prescription:

25 mcg (0.025 mg), 100 tablets (10 x 10 unit dose blisters)

Lot # N02212, Exp. Date 07/2026

50 mcg (0.050 mg), 100 tablets (10 x 10 unit dose blisters)

Lot # N02200, Exp. Date 10/2026

75 mcg (0.075 mg), 100 tablets (10 x 10 unit dose blisters)

Lot # N02172, Exp. Date 07/2026
Lot # N02296, N02288, Exp. Date 12/2026

88 mcg (0.088 mg), 100 tablets (10 x 10 unit dose blisters)

Lot # N02310, Exp. Date 01/2027

112 mcg (0.0112 mg), 100 tablets (10 x 10 unit dose blisters)

Lot # N02203, Exp. Date 09/2026

125 mcg (0.0125 mg), 100 tablets (10 x 10 unit dose blisters)

Lot # N02266, Exp. Date 11/2026

150 mcg (0.0150 mg), 100 tablets (10 x 10 unit dose blisters)

Lot # N02167, Exp. Date 07/2026

25 mcg (0.025 mg), 10 tablets (10 x 1 unit dose blisters)

Bag lot # N02212A, N02212B, Exp. Date 07/2026
Blister lot # N02212, Exp. Date 07/2026

50 mcg (0.050 mg), 10 Tablets (10 x 1 unit dose blisters)

Bag lot # N02200A, N02200B, Exp. Date 10/2026
Blister lot # N02200, Exp. Date 10/2026

125 mcg (0.0125 mg), 10 tablets (10 x 1) unit dose blisters per carton

Bag lot # N02266A, N02266B, Exp. Date 11/2026
Blister lot # N02266, Exp. Date 11/2026

150 mcg (0.0150 mg), 10 tablets (10 x 1) unit dose blisters per carton

Bag lot # N02167A, Exp. Date 07/2026
Blister lot # N02167, Exp. Date 07/2026

Drew Pittock covers national trending news for USA TODAY. He can be reached at DPittock@usatodayco.com.

Share to Facebook Share to Twitter Share by email

Featured Weekly Ad

We're always working to improve your experience. Let us know what you think.

Read Original at USA Today →